TmCD19-IL18 CAR T / Gilead - LARVOL DELTA

TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ALK • BCL2 • BCL6 • CD19

AvantGen Receives Milestone Payment for First Patient Dosed in Phase 1 Study with Kite’s Investigational CAR-T Therapy (EIN Presswire) - "AvantGen Inc...announced today that it has received the first milestone payment from Kite, a Gilead Company, for the achievement of the first patient dosed in the first Phase 1 clinical trial of a novel CAR-T construct targeting human CD19 that is also engineered to express IL18. This construct was developed in a collaboration between Kite and the University of Pennsylvania (Penn)....The Phase 1 open-label, dose-finding clinical study is initially focused on a single disease-specific cohort of subjects with Non-Hodgkin lymphoma (NCT05989204) and is being conducted by Penn as the regulatory sponsor."

Financing • Trial status • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology